Asociación Española contra el Cáncer y PharmaMar, entre los Premios Medical Economics 2009 que se entregan hoy en Madrid .

Kombination af Yondelis med 5-fluoracil-prodrugs til behandling af cancer . Nueva Patente .

Publication number: DK1689404 (T3)
Publication date: 2009-01-26
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR SAU [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: DK20040798717T 20041115
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115

Abstract not available for DK 1689404 (T3)

Yondelis y el Cancer de Melanoma .

Mechanism of action(MoA)
Tetrahydroisoquinoline alkaloid derived from the Caribbean marine tunicate, Ecteinascidia turbinata (now synthetically produced) [1]. Interacts with the minor groove of DNA and alkylates guanine at the N2 position, thus affecting various transcription factors involved in cell proliferation and the transcription-coupled nucleotide excision repair system. Blocks the cell cycle at the G2 phase. Also inhibits overexpression of multidrug resistance-1 gene (MDR-1). In preclinical models, active against different tumor types [2]. Active against melanoma in a human xenograft model [3] ...


Author(s)
The MMMP Team
Updated: Wednesday, January 7, 2009 07:29 PM

Yondelis , National Cancer Institute ( EEUU ), en su revision de Enero de Fase II Pediatrica que se lleva a cabo en 68 Hospitales de EEUU y Canada .

Yondelis ( ET - 743 ) in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors


This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), January 2009
Last Updated: January 27, 2009